562 related articles for article (PubMed ID: 26361042)
21. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: Is It Different between Over and Under 50 Years of Age?
Monabati A; Vahedi A; Safaei A; Noori S; Mokhtari M; Vahedi L; Zamani M
Asian Pac J Cancer Prev; 2016; 17(4):2285-9. PubMed ID: 27221931
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
[TBL] [Abstract][Full Text] [Related]
23. The presence of Epstein-Barr virus (EBV) in diffuse large B-cell lymphomas (DLBCLs) in Turkey: special emphasis on 'EBV-positive DLBCL of the elderly'.
Uner A; Akyurek N; Saglam A; Abdullazade S; Uzum N; Onder S; Barista I; Benekli M
APMIS; 2011 Apr; 119(4-5):309-16. PubMed ID: 21492232
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression.
Jiang XN; Yu BH; Yan WH; Lee J; Zhou XY; Li XQ
Oncoimmunology; 2020; 9(1):1683346. PubMed ID: 32002294
[No Abstract] [Full Text] [Related]
25. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.
Zhao CX; Yan ZX; Wen JJ; Fu D; Xu PP; Wang L; Cheng S; Hu JD; Zhao WL
Mol Cancer; 2021 Dec; 20(1):153. PubMed ID: 34852843
[TBL] [Abstract][Full Text] [Related]
26. EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.
Xue T; Wang WG; Zhou XY; Li XQ
Pathology; 2018 Dec; 50(7):725-729. PubMed ID: 30389217
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report.
Yu M; Zhang Q; Xu S; Yin T; Li F
Anticancer Drugs; 2022 Jan; 33(1):e769-e775. PubMed ID: 34387604
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.
Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX
Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis.
Song CG; Huang JJ; Li YJ; Xia Y; Wang Y; Bi XW; Jiang WQ; Huang HQ; Lin TY; Li ZM
PLoS One; 2015; 10(7):e0133973. PubMed ID: 26222726
[TBL] [Abstract][Full Text] [Related]
30. An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified.
Hoffmann JC; Chisholm KM; Cherry A; Chen J; Arber DA; Natkunam Y; Warnke RA; Ohgami RS
Hum Pathol; 2016 Feb; 48():9-17. PubMed ID: 26772393
[TBL] [Abstract][Full Text] [Related]
31. Programmed cell death-ligand 1 (PD-L1)
Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
[TBL] [Abstract][Full Text] [Related]
32. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
[TBL] [Abstract][Full Text] [Related]
33. Reappraisal of Epstein-Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells.
Ohashi A; Kato S; Okamoto A; Inaguma Y; Satou A; Tsuzuki T; Emi N; Okamoto M; Nakamura S
Histopathology; 2017 Jul; 71(1):89-97. PubMed ID: 28231401
[TBL] [Abstract][Full Text] [Related]
34. A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly.
Wang E; Papavassiliou P; Sebastian S
Pathol Res Pract; 2012 Jun; 208(6):363-7. PubMed ID: 22572037
[TBL] [Abstract][Full Text] [Related]
35. pSTAT3 and MYC in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Teoh SH; Khoo JJ; Abdul Salam DSD; Peh SC; Cheah SC
Malays J Pathol; 2019 Dec; 41(3):273-281. PubMed ID: 31901912
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr Virus-Positive Diffuse Large B cell Lymphoma in the Experience of a Tertiary Medical Center in Poland.
Ziarkiewicz M; Wołosz D; Dzieciątkowski T; Wilczek E; Dwilewicz-Trojaczek J; Jędrzejczak WW; Gierej B; Ziarkiewicz-Wróblewska B
Arch Immunol Ther Exp (Warsz); 2016 Apr; 64(2):159-69. PubMed ID: 26084760
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus-specific CD8(+) T lymphocytes from diffuse large B cell lymphoma patients are functionally impaired.
Cárdenas D; Vélez G; Orfao A; Herrera MV; Solano J; Olaya M; Uribe AM; Saavedra C; Duarte M; Rodríguez M; López M; Fiorentino S; Quijano S
Clin Exp Immunol; 2015 Nov; 182(2):173-83. PubMed ID: 26174440
[TBL] [Abstract][Full Text] [Related]
38. Development of EBV-encoded small RNA targeted PCR to classify EBV positive diffuse large B-cell lymphoma (DLBCL) of the elderly.
Lee J; Park M; Lee MH; Woo HJ; Kim HW; Yang JY; Eom YB; Kim SH; Yoo C; Kim JB
Int J Clin Exp Pathol; 2015; 8(7):7859-68. PubMed ID: 26339350
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
[TBL] [Abstract][Full Text] [Related]
40. TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients.
Cho J; Kim E; Yoon SE; Kim SJ; Kim WS
Cancer; 2023 May; 129(10):1502-1512. PubMed ID: 36812290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
